Robert S Negrin
Overview
Explore the profile of Robert S Negrin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
6920
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bravo D, Vaidyanathan S, Baker J, Sinha V, Tsai E, Roozdar P, et al.
bioRxiv
. 2025 Feb;
PMID: 39896581
Modulator agents that restore cystic fibrosis transmembrane conductance regulator (CFTR) function have revolutionized outcomes in cystic fibrosis, an incurable multisystem disease. Barriers exist to modulator use, making local CFTR gene...
2.
Meyer E, Pavlova A, Villar-Prados A, Bader C, Xie B, Muffly L, et al.
Blood
. 2025 Jan;
PMID: 39792934
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy limited by graft-versus-host disease (GVHD). In preclinical studies and early-phase clinical studies enrichment of donor regulatory T cells (Tregs) appears to...
3.
Boonchalermvichian C, Yan H, Gupta B, Rubin A, Baker J, Negrin R
Front Transplant
. 2024 Jul;
3:1353803.
PMID: 38993780
Invariant Natural Killer T cell therapy is an emerging platform of immunotherapy for cancer treatment. This unique cell population is a promising candidate for cell therapy for cancer treatment because...
4.
Vijayan V, Yan H, Lohmeyer J, Prentiss K, Patil R, Barbarito G, et al.
Blood Adv
. 2024 May;
8(14):3691-3704.
PMID: 38701354
Despite therapeutic advancements, graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HSCT). In current models of GVHD, tissue injury induced by cytotoxic conditioning regimens, along with...
5.
Veilleux O, Socola F, Arai S, Frank M, Johnston L, Lowsky R, et al.
Am J Hematol
. 2024 Apr;
99(8):1485-1491.
PMID: 38661220
Autologous hematopoietic cell transplantation (AHCT) is often used as a consolidation for patients with peripheral T-cell lymphomas (PTCLs) due to the poor prognosis associated with this heterogenous group of disorders....
6.
Hamilton M, Craig E, Gentille Sanchez C, Mina A, Tamaresis J, Kirmani N, et al.
Blood Adv
. 2024 Mar;
8(12):3314-3326.
PMID: 38498731
Chimeric antigen receptor (CAR) T cells directed against CD19 (CAR19) are a revolutionary treatment for B-cell lymphomas (BCLs). CAR19 cell expansion is necessary for CAR19 function but is also associated...
7.
Bernardi C, Garibotto V, Mobashwera B, Negrin R, Alam I, Simonetta F
J Nucl Med
. 2024 Feb;
PMID: 38360050
Noninvasive molecular imaging of acute graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation has great potential to detect GvHD at the early stages, aid in grading of the disease,...
8.
Bader C, Pavlova A, Lowsky R, Muffly L, Shiraz P, Arai S, et al.
Blood Adv
. 2023 Dec;
8(5):1105-1115.
PMID: 38091578
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for hematological malignancies for which graft-versus-host disease (GVHD) remains a major complication. The use of donor T-regulatory cells (Tregs) to prevent...
9.
Maas-Bauer K, Kohler N, Stell A, Zwick M, Acharya S, Rensing-Ehl A, et al.
J Leukoc Biol
. 2023 Sep;
115(2):401-409.
PMID: 37742056
Invariant natural killer T cells are a rare, heterogeneous T-cell subset with cytotoxic and immunomodulatory properties. During thymic development, murine invariant natural killer T cells go through different maturation stages...
10.
Spinner M, Sica R, Tamaresis J, Lu Y, Chang C, Lowsky R, et al.
Blood
. 2023 Mar;
141(22):2727-2737.
PMID: 36857637
The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has evolved significantly over the past decade after the approval of brentuximab vedotin (BV) and the programmed death-1 (PD-1) inhibitors....